***Background.*** DAL is lipoglycopeptide antibiotic which is a highly protein bound (93%) with a long elimination half-life in plasma. DAL exhibits activity against Gram-positive organisms, including MRSA, with an *in vitro* MIC~90~ of 0.06 mg/ml. The objective of this study was to characterize the PK of DAL in bone and associated tissues in patients undergoing joint surgery.

***Methods.*** Adults scheduled for joint surgery (N = 31) were administered 1 g of DAL infused over 30 minutes prior to scheduled surgery. Patients were assigned to 1 of 6 cohorts and had serial plasma PK samples collected up to 45 days post-dose plus 1 bone PK sample collected at 12, 24, 72, 168, 240 or 336 hr post dose. Samples were analyzed for DAL in plasma, synovial fluid, skin, cartilage and bone using LC-MS/MS. A population PK model was fit to plasma and bone PK data using NONMEM and covariate analysis was performed. Allometry was used to determine the total amount of bone tissue and to estimate the amount of DAL in bone.

***Results.*** DAL concentrations in bone, synovial fluid, synovial tissue, and skin exceeded the DAL MIC~90~ against *S. aureus* of 0.06 mg/mL. DAL concentrations in bone appeared to remain relatively constant for a period of 14 days after a single dose. The mean bone:plasma AUC penetration ratio was 13.9%.

  -----------------------------------------------------------------------------------------------------------------------------------------------
                             Mean concentration±SD (no. of samples)                                                               
  -------------------------- ---------------------------------------- -------------- -------------- -------------- -------------- ---------------
  Plasma (mg/mL)             85.3±18.9 (31)                           \--            \--            \--            \--            15.3±4.1 (31)

  Synovium (mg/g)\*          25.0±0 (3)                               17.9±7.8 (3)   19.5±4.9 (3)   19.2±8.9 (4)   25.0±0 (2)     15.9± 7.9 (3)

  Synovial fluid (mg/mL)\*   22.9 (1)                                 27.4±10.8\     19.2±4.9 (3)   11.6±3.3 (2)   13.9±1.0 (3)   6.2±1.7 (2)
                                                                      (4)                                                         

  Bone (mg/g)                6.3±3.1 (5)                              5.0±3.5 (5)    4.6±3.8 (5)    3.8±2.7 (5)    3.7±2.2 (5)    4.1±1.6 (5)

  Skin (mg/g)\*              19.4±7.9 (2)                             12.5±6.5 (3)   13.8±1.4 (2)   15.7±1.0 (2)   21.6 (1)       13.8±2.1 (2)
  -----------------------------------------------------------------------------------------------------------------------------------------------

\* Concentrations above the upper limit of quantification are reported as 25 µg/unit

***Conclusion.*** Dalbavancin distributes into bone and associated tissue, including synovium. Bone penetration was 13.9% based upon total drug AUC and the high degree of protein binding suggests that the overall penetration is high relative to free-drug plasma concentrations. This study demonstrates that dalbavancin accumulates in bone and supports further study in patients with osteomyelitis and prosthetic joint infections.
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